 2018;36:1556-1563.
 65. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-
L1) in the treatment of advanced human cancer. Clin Cancer Res . 
2013;19:1021-1034.
 66. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 
therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol . 2018;8:86.
 67. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8 + lymphocyte infiltration is an independent favorable prognostic 
indicator in basal-like breast cancer. Breast Cancer Res . 2012;14:R48.
 68. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of 
tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addi -
tion of docetaxel to doxorubicin with doxorubicin-based chemother -
apy: BIG 02-98. J Clin Oncol . 2013;31:860-867.
 69. Nanda R, Liu M, Yao C, Asare S, Hylton N, Van’t Veer L. 
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 [abstract 506]. J Clin Oncol . 
2017;35.
 70. Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes 
PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature . 2018;553:91-95.
 71. Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments 
antitumor immunity by enhancing T-cell activation. Cancer Discov . 
2018;8:216-233.
 72. Ladd B, Mazzola AM, Bihani T, et al. Effective combination thera -
pies in preclinical endocrine resistant breast cancer models harboring 
ER mutations. Oncotarget . 2016;7:54120-54136.
 73. Scott GK, Chu D, Kaur R, et al. ERpS294 is a biomarker of ligand or 
mutational ERalpha activation and a breast cancer target for CDK2 inhibition. Oncotarget . 2017;8:83432-83445.
 74. Mao C, Livezey M, Kim JE, Shapiro DJ. Antiestrogen resistant cell 
lines expressing estrogen receptor alpha mutations upregulate the un -
folded protein response and are killed by BHPI. Sci Rep . 2016;6:34753.
 75. Gelsomino L, Panza S, Giordano C, et al. Mutations in the estrogen 
receptor alpha hormone binding domain promote stem cell pheno -
type through notch activation in breast cancer cell lines. Cancer Lett . 
2018;428:12-20.
 76. Chen D, Riedl T, Washbrook E, et al. Activation of estrogen receptor 
alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell . 2000;6:127-137.
 77. Yardley D, Ismail-Khan R, Klein P. Results of ENCORE 301, a 
randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER +) 
breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). J Clin Oncol . 2011;29:268.
 78. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase 
II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing 
 10970142, 2019, 21, Downloaded from https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32345 by Consorci De Serveis Universitaris De Catalunya, Wiley Online Library on [07/06/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
Review Article
3728
Cancer   November 1, 2019on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol . 
2013;31:2128-2135.
 79. Yeruva SLH, Zhao F, Miller KD, et al. E2112: randomized phase 
iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer . 2018;4:1.
 80. Kimura M, Hanamura T, Tsuboi K, et al. Acquired resistance to 
everolimus in aromatase inhibitor-resistant breast cancer. Oncotarget . 
2018;9:21468-21477.
 81. Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation 
and acquired resistance to CDK4/6 inhibition in estrogen receptor- positive breast cancer. Cancer Res . 2016;76:2301-2313.
 82. Condorelli R, Spring L, O’Shaughnessy J, et al. Polyclonal RB1  
mutations and acquired resistance to CDK 4/6 inhibitors in patients 
with metastatic breast cancer. Ann Oncol . 2018;29:640-645. 83. de Leeuw R, McNair C, Schiewer MJ, et al. MAPK reliance via 
acquired CDK4/6 inhibitor resistance in cancer. Clin Cancer Res . 
2018;24:4201-4214.
 84. Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA in -
terference screen reveals a role for PDK1 in acquired resistance 
to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res . 
2017;77:2488-2499.
 85. Malorni L, Piazza S, Ciani Y, et al.